This case report highlights the potential inadequacy of prophylactic LMWH in preventing fatal pulmonary embolism in patients with hyperosmolar hyperglycaemic state, suggesting a need for research into full-dose anticoagulation.
Answers are grounded in this paper and cite their sources.
Does not support changing LMWH prophylaxis in HHS; hypothesis-generating for trials of intensified anticoagulation.
Diabetes mellitus and, in particular, the hyperosmolarity associated with the hyperosmolar hyperglycaemic state (HHS) is associated with an increased risk of thrombotic events. This risk is acknowledged by the authors of the national HHS guideline who recommend prophylactic low molecular weight heparin (LMWH) for all patients with HHS for the full duration of their admission.We present a case of fatal pulmonary embolism in a 39-year old man admitted with HHS who was treated according to local hospital trust and national guidance with prophylactic LMWH.In the absence of evidence from randomised studies comparing prophylactic and treatment dose anti- coagulation in thrombosis prevention in HHS further research is needed to facilitate development of evidence-based guidelines.
No takes yet. Share an insight, caveat, or question.
Wordsworth et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: